Disease · MONDO_0018905
Comparisons in its trials154
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 154
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events | 269 of 701 | 312 of 702 | 1,403 | NCT01287741 | Trial comparisons |
| Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: deaths from any cause | 78 of 416 | 78 of 418 | 834 | NCT01855750 | Trial comparisons |
| Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: serious adverse events | 221 of 416 | 143 of 418 | 834 | NCT01855750 | Trial comparisons |
| Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events | 224 of 395 | 173 of 386 | 781 | NCT00486759 | Trial comparisons |
| Arm A vs Arm B: Number of Participants With Treatment Emergent Adverse Events (AEs) | 352 of 371 | 347 of 369 | 740 | NCT01724021 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 126 of 371 | 116 of 369 | 740 | NCT01724021 | Trial comparisons |
| Rituximab SC vs Rituximab IV: serious adverse events | 155 of 369 | 77 of 203 | 572 | NCT01649856 | Trial comparisons |
| Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP: deaths from any cause | 85 of 285 | 88 of 285 | 570 | NCT02285062 | Trial comparisons |
| Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP: serious adverse events | 104 of 283 | 88 of 284 | 567 | NCT02285062 | Trial comparisons |
| Rituximab SC vs Rituximab IV: Number of Participants With an Event-Free Survival (EFS) Event | 116 of 342 | 53 of 177 | 519 | NCT01649856 | Trial comparisons |
| Rituximab SC vs Rituximab IV: Number of Participants With Progression, Relapse, or Death | 95 of 342 | 38 of 177 | 519 | NCT01649856 | Trial comparisons |
| Rituximab SC vs Rituximab IV: Number of Deaths | 56 of 342 | 22 of 177 | 519 | NCT01649856 | Trial comparisons |
| Arm A - R-CHOP vs Arm B - DA-EPOCH-R: deaths from any cause | 53 of 250 | 56 of 241 | 491 | NCT00118209 | Trial comparisons |
| Arm A - R-CHOP vs Arm B - DA-EPOCH-R: serious adverse events | 232 of 243 | 214 of 237 | 480 | NCT00118209 | Trial comparisons |
| Tafasitamab + Bendamustine vs Rituximab + Bendamustine: deaths from any cause | 129 of 226 | 127 of 227 | 453 | NCT02763319 | Trial comparisons |
| Rituximab + Chemotherapy vs Ofatumumab + Chemotherapy: Number of Participants Completing Autologous Stem Cell Transplant (ASCT) | 83 of 223 | 74 of 222 | 445 | NCT01014208 | Trial comparisons |
| Rituximab + Chemotherapy vs Ofatumumab + Chemotherapy: serious adverse events | 115 of 223 | 118 of 222 | 445 | NCT01014208 | Trial comparisons |
| Tafasitamab + Bendamustine vs Rituximab + Bendamustine: Number of Participants With Any Grade 3 or Higher TEAE | 191 of 219 | 159 of 225 | 444 | NCT02763319 | Trial comparisons |
| Tafasitamab + Bendamustine vs Rituximab + Bendamustine: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 215 of 219 | 215 of 225 | 444 | NCT02763319 | Trial comparisons |
| Tafasitamab + Bendamustine vs Rituximab + Bendamustine: serious adverse events | 115 of 219 | 100 of 225 | 444 | NCT02763319 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018905/comparisons